# Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome

> **NCT00004918** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 69 (estimated)

## Conditions studied

- Accelerated Phase Chronic Myelogenous Leukemia
- Adult Acute Myeloid Leukemia in Remission
- Chronic Phase Chronic Myelogenous Leukemia
- Previously Treated Myelodysplastic Syndromes
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Excess Blasts in Transformation
- Relapsing Chronic Myelogenous Leukemia

## Interventions

- **BIOLOGICAL:** PR1 leukemia peptide vaccine
- **DRUG:** Montanide ISA 51 VG
- **BIOLOGICAL:** sargramostim
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00004918
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1999-12
- **Primary completion:** 2007-12
- **Final completion:** —
- **Target enrollment:** 69 (ESTIMATED)
- **Last updated:** 2013-01-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00004918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00004918, "Vaccine Therapy Plus Immune Adjuvant in Treating Patients With Chronic Myeloid Leukemia, Acute Myeloid Leukemia, or Myelodysplastic Syndrome". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT00004918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*